Previous studies have reported that ccRCC is prone to immune cell infiltration and, thus, is highly responsive to immunotherapies that inhibit the interactions between immune cells and tumor cells by targeting CTLA4, PD-1, and PD-L1 (2). This evidence concerns the gene PDCD1 and nonpapillary renal cell carcinoma.